Results 181 to 190 of about 6,160,574 (237)

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

open access: yesArthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin   +7 more
wiley   +1 more source

Individuals With Multijoint Osteoarthritis Demonstrate Larger Longitudinal Declines in Frailty: Data From the Canadian Longitudinal Study on Aging

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this study was to test the hypothesis that multijoint osteoarthritis would modify the relation between time and frailty progression, in which more affected joints would lead to larger declines over six years compared to those without osteoarthritis using data from the Canadian Longitudinal Study on Aging.
Carson Halliwell   +2 more
wiley   +1 more source

Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is associated with numerous facial manifestations for which patients may engage in cosmetic therapies. It is unclear how patients with SSc use these therapies. This study sought to characterize patient engagement and experiences with cosmetic therapies for SSc‐related and non‐SSc–related facial changes.
Zachary Warren   +11 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy